A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/00 (2006.01) A61K 38/16 (2006.01) A61K 38/17 (2006.01) A61K 38/19 (2006.01) A61K 39/00 (2006.01) A61K 39/38 (2006.01) A61K 39/395 (2006.01)
Patent
CA 2461666
The current invention provides for methods of immunotherapy using a combination of epitope-specific and cytokine or anticytokine immunotherapy. The method provides for modulation of pathogenic immune response and includes the identification of molecules comprising specific epitopes involved in a particular disease state of interest, administration of the epitope-specific molecule in conjunction with the cytokine or anticytokine, and downstream modification of the administration of the cytokine/anticytokine relative to the administration of the epitope-specific molecule. Figure 1 is a graph showing the effects on mean arthritis scores calculated into four groups following induction of Adjuvant Arthritis.
La présente invention concerne des méthodes d'immunothérapie faisant appel à une combinaison d'immunothérapies anticytokine ou cytokine et spécifiques des épitopes. Cette méthode consiste à moduler des réponses immunes pathogènes et comprend l'identification des molécules renfermant des épitopes spécifiques impliqués dans un trouble particulier d'intérêt, l'administration de la molécule spécifique d'un épitope conjointement à la cytokine ou à l'anticytokine, et la modification en aval de l'administration de la cytokine/anticytokine par rapport à l'administration de la molécule spécifique d'un épitope.
Albani Salvatore
Martini Alberto
Martini Alberto
Osler Hoskin & Harcourt Llp
The Regents Of The University Of California
LandOfFree
Combination therapies for immune mediated diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapies for immune mediated diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapies for immune mediated diseases will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1369754